Clinical Trial Update: 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating 16-week efficacy of secukinumab in active ankylosing spondylitis. The report also covers two-year long-term safety and efficac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Ankylosing Spondylitis | Phase 3 | Status: COMPLETED | Results posted: 2017-01-27